TABLE 1

Patient Characteristics

Patient no.	Age (y)	Sex	Location of primary	Tumor differentiation	Tumor sites*	Therapy before PET^†
1	70	M	Mediastinum	Carcinoid	b, m, lu, li	irrad, cht, oct-h
2	42	M	Pancreas	Carcinoid	p	None
3	52	F	Unknown	Carcinoid	b, o	None
4	74	F	Unknown	Carcinoid	m, li, o	surg, cht
5	67	M	Ileocecal	Carcinoid	b, li, o	surg, emb
6	72	F	Pancreas	Carcinoid	b, li	surg, irrad, cht, oct-h
7	67	F	Unknown	Carcinoid	o	surg
8	56	M	Ileocecal	Carcinoid	b, m, li, o	surg, emb, oct-c, IFN
9	45	F	Pancreas	Glucagonoma	b, li, o	surg, irrad, IFN, oct-c, oct-h
10	60	M	Pancreas	Somatostatinoma	b, li, o	surg, IFN, cht, oct-h
11	46	M	Pancreas	Carcinoid	li, p	surg, emb
12	61	M	Unknown	Carcinoid	b, m, lu, li	cht
13	45	M	Ileocecal	Carcinoid	b, li	cht, emb
14	70	M	Unknown	Carcinoid	li	surg
15	53	M	Unknown	Gastrinoma	li	surg, oct-h
16	61	F	Ileocecal	Carcinoid	m, lu, li, o	surg, emb, oct-h
17	72	F	Unknown	Carcinoid	b, m, li, o	None
18	47	F	Pancreas	Gastrinoma	li, o	surg
19	57	M	Pancreas	Carcinoid	li, p, o	cht, IFN, oct-c
20	63	F	Lung	Carcinoid	b, m, lu	surg, cht
21	69	F	Stomach	Gastrinoma	o	surg
22	81	M	Rectum	Carcinoid	b, o	irrad
23	59	M	Unknown	Carcinoid	lu, li,	surg, cht, oct-h

↵* Tumor sites: b = bone; m = mediastinal; lu = lung; li = liver; p = pancreatic; o = others.
↵^† Therapies: irrad = irradiation; cht = chemotherapy; oct-h = ⁹⁰Y-labeled octreotide; surg = surgery; emb = embolization; oct-c = inactive octreotide; IFN = interferon-α.